Detalhe da pesquisa
1.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood
; 138(21): 2042-2050, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407543
2.
Chronic myeloid leukaemia.
Lancet
; 398(10314): 1914-1926, 2021 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425075
3.
Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Future Oncol
; 15(3): 257-269, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30251548
4.
Chronic Myeloid Leukemia: What Is the Best Strategy to Start and Monitor Treatment Outside Academic Centers?
Curr Oncol Rep
; 20(1): 4, 2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29383451
5.
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Br J Haematol
; 179(2): 219-228, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699641
6.
[Chronic myelogenous leukemia: monitoring and predictors of a favorable response to treatment with imatinib]. / Leucemia mieloide crónica. Monitoreo y factores predictivos de una respuesta favorable en el tratamiento con imatinib.
Medicina (B Aires)
; 77(3): 161-166, 2017.
Artigo
em Espanhol
| MEDLINE | ID: mdl-28643670
7.
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.
Blood Cells Mol Dis
; 59: 129-33, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27282582
8.
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Blood
; 123(4): 494-500, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24311723
9.
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Cancer Invest
; 2015 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26279306
10.
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Cancer Invest
; 33(9): 451-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26288116
11.
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood
; 119(5): 1123-9, 2012 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160483
12.
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
Clin Lymphoma Myeloma Leuk
; 24(3): 158-164, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973457
13.
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Blood Adv
; 8(10): 2361-2372, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447114
14.
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?
Semin Hematol
; 60(4): 209-214, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517949
15.
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
J Hematol Oncol
; 16(1): 43, 2023 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120577
16.
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Front Immunol
; 14: 1241600, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37818372
17.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Blood Adv
; 7(12): 2794-2806, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696464
18.
Challenges in Chronic Myeloid Leukemia Management in South America.
Curr Hematol Malig Rep
; 16(5): 440-447, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655027
19.
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Blood Adv
; 5(23): 4855-4863, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34438444
20.
COVID-19 in chronic myeloid leukemia patients in Latin America.
Leuk Lymphoma
; 62(13): 3212-3218, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34254886